act is expected in the first quarter of the year, driven both by access expansion and typical seasonal copay resets in the period.

Beyond launching Nemluvio in five International markets in 2025, Galderma continued to make regulatory progress, with approvals now secured in Canada and South Korea, and additional submissions underway.

Scientific leadership and excellence in medical education

In 2025, Galderma reaffirmed its leadership in dermatology, supported by an innovative, sciencebased portfolio, continued progress on its scientific agenda, and a strong presence at scientific congresses and key industry events.

Among the highlights, Galderma presented longterm Nemluvio data in prurigo nodularis and atopic dermatitis, reinforcing its consistent safety profile and durable clinical efficacy across both indications up to two years, at the European Academy of Dermatology and Venereology (EADV) 2025, the Revolutionizing Atopic Dermatitis (RAD) Confe
=*=*=*=*=*=
当前为第15/55页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页